137 research outputs found
Update on the use of fibrates: focus on bezafibrate
Low-density lipoprotein-cholesterol (LDL-C) is a well established coronary heart disease (CHD) risk factor. However, the ability of this metabolic risk factor alone to identify individuals at rigk for future CHD events is limited. The raised triglycerides-low high-density lipoprotein-cholesterol (HDL-C) dyslipidaemia was shown to be an important cardiovascular risk factor independently of LDL-C levels. Fibric acid derivatives (fibrates) have been used in clinical practice for more than 2 decades as a class of agents known to decrease triglyceride levels while substantially increasing HDL-C levels. Through peroxisome proliferator-activated α-receptors, fibrates have a significant impact on the synthesis of several apolipoproteins and enzymes of lipoprotein metabolism as well as on the expression of several genes involved in fibrinolysis and inflammation. Data from recent primary and secondary prevention clinical trials demonstrate the efficacy of fibrate therapy in patients with the raised triglycerides-low HDL-C dyslipidaemia. This review summarizes current data regarding mechanism of action and the metbolic effects of fibrates, as well as results from major clinical trials on the efficacy of this mode of lipid lowering therapy. In addition, recent data from subgroup analyses of the Bezafibrate Infarction Prevention trial, demonstrating several important metabolic and long-term cardiovascular effects of bezafibrate therapy, are detailed
Pricing Multi-Unit Markets
We study the power and limitations of posted prices in multi-unit markets,
where agents arrive sequentially in an arbitrary order. We prove upper and
lower bounds on the largest fraction of the optimal social welfare that can be
guaranteed with posted prices, under a range of assumptions about the
designer's information and agents' valuations. Our results provide insights
about the relative power of uniform and non-uniform prices, the relative
difficulty of different valuation classes, and the implications of different
informational assumptions. Among other results, we prove constant-factor
guarantees for agents with (symmetric) subadditive valuations, even in an
incomplete-information setting and with uniform prices
Low-Afterglow, High-Refractive-Index Liquid Scintillators for Fast-Neutron Spectrometry and Imaging Applications
For ion and neutron spectrometry and imaging applications at a high intensity
pulsed laser facility, fast liquid scintillators with very low afterglow are
required. Furthermore, neutron imaging with fiber (or liquid-core) capillary
arrays calls for scintillation materials with high refractive index. To this
end, we have examined various combinations of established mixtures of fluors
and solvents, that were enriched alternatively with nitrogen or oxygen.
Dissolved molecular oxygen is known to be a highly effective quenching agent,
that efficiently suppresses the population of the triplet states in the fluor,
which are primarily responsible for the afterglow. For measuring the glow
curves of scintillators, we have employed the time-correlated single photon
counting (TCSPC) technique, characterized by high dynamic range of several
orders of magnitude in light intensity. In this paper we outline the
application for the fast scintillators, briefly present the scintillation
mechanism in liquids, describe our specific TCSPC method and discuss the
results.Comment: 5 pages, Contribution to SORMA WEST 2008. To be published in IEEE
TNS, 200
Identification of a Proliferation Gene Cluster Associated with HPV E6/E7 Expression Level and Viral DNA Load in Invasive Cervical Carcinoma
Specific HPV DNA sequences are associated with more than 90% of invasive
carcinomas of the uterine cervix. Viral E6 and E7 oncogenes are key mediators
in cell transformation by disrupting TP53 and RB pathways. To investigate
molecular mechanisms involved in the progression of invasive cervical
carcinoma, we performed a gene expression study on cases selected according to
viral and clinical parameters. Using Coupled Two-Way Clustering and Sorting
Points Into Neighbourhoods methods, we identified a Cervical Cancer
Proliferation Cluster composed of 163 highly correlated transcripts, many of
which corresponded to E2F pathway genes controlling cell proliferation, whereas
no primary TP53 targets were present in this cluster. The average expression
level of the genes of this cluster was higher in tumours with an early relapse
than in tumours with a favourable course (P=0.026). Moreover, we found that
E6/E7 mRNA expression level was positively correlated with the expression level
of the cluster genes and with viral DNA load. These findings suggest that HPV
E6/E7 expression level plays a key role in the progression of invasive
carcinoma of the uterine cervix via the deregulation of cellular genes
controlling tumour cell proliferation. HPV expression level may thus correspond
to a biological marker useful for prognosis assessment and specific therapy of
the disease
Influence of anesthesia on hemodynamic assessment of mitral stenosis severity
Background: The treatment of choice for severe rheumatic mitral stenosis (MS) is balloon mitral valvuloplasty (BMV). Assessment of MS severity is usually performed by echocardiography. Before performing BMV, invasive hemodynamic assessment is also performed. The effect of anesthesia on the invasive assessment of MS severity has not been studied. The purpose of the present study was to assess changes in invasive hemodynamic measurement of MS severity before and after induction of general anesthesia.
Methods: The medical files of 22 patients who underwent BMV between 2014 and 2020 were reviewed. Medical history, laboratory, echocardiographic and invasive measurements were collected. Anesthesia induction was performed with etomidate or propofol. Pre-procedural echocardiographic measurements of valve area using pressure half time, and continuity correlated well with invasive measurements using the Gorlin formula.
Results: After induction of anesthesia the mean mitral valve gradient dropped by 2.4 mmHg (p = 0.153) and calculated mitral valve area (MVA) increased by 0.2 cm2 (p = 0.011). A wide variability in individual response was observed. While a drop in gradient was noted in 14 patients, it increased in 7. Gorlin derived MVA rose in most patients but dropped in 4. Assuming a calculated MVA of 1.5 cm2 and below to define clinically significant MS, 4 patients with pre-induction MVA of 1.5 cm2 or below had calculated MVA above 1.5 cm2 after induction.
Conclusions: The impact of general anesthesia on the hemodynamic assessment of MS is heterogeneous and may lead to misclassification of MS severity
Left atrial size predicts long-term outcome after balloon mitral valvuloplasty
Background: The treatment of choice for severe rheumatic mitral stenosis is balloon mitral valvuloplasty (BMV). Numerous predictors of immediate and long-term procedural success have been described. The aims of this study were to describe our experience with BMV over the last decade and to evaluate predictors of long-term event-free survival.
Methods: Medical records were retrospectively analyzed of patients who underwent BMV between 2009 and 2021. The primary outcome was a composite endpoint of all-cause mortality, mitral valve replacement (MVR), and repeat BMV. Long-term event-free survival was estimated using the Kaplan-Meier curves. Logistic regression was used to create a multivariate model to assess pre-procedural predictors of the primary outcome.
Results: A total of 96 patients underwent BMV during the study period. The primary outcome occurred in 36 patients during 12-year follow-up: 1 (1%) patient underwent re-BMV, 28 (29%) had MVR, and 8 (8%) died. Overall event-free survival was 62% at 12 years. On multivariate analysis, pre-procedural left atrial volume index (LAVI) > 80 mL/m2 had a significant independent influence on event-free survival, as did previous mitral valve procedure and systolic pulmonary arterial pressure above 50 mmHg.
Conclusion: Despite being a relatively low-volume center, excellent short and long-term results were demonstrated, with event-free survival rates consistent with previous studies from high-volume centers. LAVI independently predicted long-term event-free survival
CCL24 regulates biliary inflammation and fibrosis in primary sclerosing cholangitis
ˆCCL24 is a pro-fibrotic, pro-inflammatory chemokine expressed in several chronic fibrotic diseases. In the liver, CCL24 plays a role in fibrosis and inflammation, and blocking CCL24 led to reduced liver injury in experimental models. We studied the role of CCL24 in primary sclerosing cholangitis (PSC) and evaluated the potential therapeutic effect of blocking CCL24 in this disease. Multidrug resistance gene 2-knockout (Mdr2-/-) mice demonstrated CCL24 expression in liver macrophages and were used as a relevant experimental PSC model. CCL24-neutralizing monoclonal antibody, CM-101, significantly improved inflammation, fibrosis, and cholestasis-related markers in the biliary area. Moreover, using spatial transcriptomics, we observed reduced proliferation and senescence of cholangiocytes following CCL24 neutralization. Next, we demonstrated that CCL24 expression was elevated under pro-fibrotic conditions in primary human cholangiocytes and macrophages, and it induced proliferation of primary human hepatic stellate cells and cholangiocytes, which was attenuated following CCL24 inhibition. Correspondingly, CCL24 was found to be highly expressed in liver biopsies of patients with PSC. CCL24 serum levels correlated with Enhanced Liver Fibrosis score, most notably in patients with high alkaline phosphatase levels. These results suggest that blocking CCL24 may have a therapeutic effect in patients with PSC by reducing liver inflammation, fibrosis, and cholestasis
Transcatheter edge-to-edge mitral valve repair in patients with acute decompensated heart failure due to severe mitral regurgitation
Background: Transcatheter edge-to-edge mitral valve repair (TEER) has been established as a therapy for severe symptomatic mitral regurgitation (MR) in stable patients, and it has recently emerged as a reasonable option for acutely ill patients. The aim of this study was to evaluate the safety and efficacy of TEER in hospitalized patients with acute decompensated heart failure (ADHF) and severe MR that was deemed to play a major role in their deterioration.
Methods: We included 31 patients who underwent emergent TEER for MR ≥ 3+ from 2012 to 2022 at Sheba Medical Center. Outcomes included procedural safety, procedural success, all-cause mortality, heart failure readmission, and functional improvement. Outcomes were evaluated at 3 months and at 1 year. Data were obtained retrospectively by chart review.
Results: Implantation of a TEER device was achieved in 97% of patients, and reduction in MR severity of at least two grades and final MR ≤ 2+ at discharge was achieved in 74%. No intra-procedural mortality or life-threatening complications were noted. Mortality at 30 days was 23%. No excess mortality occurred beyond 6 months, with a total mortality of 41%. At 1 year all survivors had MR ≤ 2+, all were free of heart failure hospitalizations, and 88% were at New York Heart Association class ≤ II.
Conclusions: Mitral valve TEER for patients with ADHF and significant MR is safe, feasible, and achieves substantial reduction in MR severity. Despite high early mortality, procedural success is associated with good long-term clinical outcomes for patients surviving longer than 6 months
- …